Latest News

Sign up to receive our news releases

More SomaLogic News

SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies

CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on key disease biomarkers.

read more

SomaLogic Announces Registration Statement Declared Effective and Reports 176% Y/Y Second Quarter and 187% First Half of 2021 Revenue Growth

CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the registration statement for their business combination has been declared effective by the US Securities Exchange Commission (“SEC”), with a CM Life Sciences II special meeting date set for August 31, 2021 for shareholders of record as of July 2, 2021 and the transaction expected to close promptly thereafter.

read more

Events Archive

Global NASH Congress | Webinar

Our presentation at the virtual 2021 Global Nash Congress features Dr. Stephen Williams , who discusses SomaLogics development of serum proteomic tests for liver biopsy components and diagnosis of at-risk NASH. Watch now to learn how these tests can help streamline clinical trials.

watch here

For older news and press releases, please visit our archive.